CHEMOTHERAPY Current drugs still have potential in advanced ovarian cancer

Thomas Högberg

doi:10.1038/nrclinonc.2010.37

CHEMOTHERAPY Current drugs still have potential in advanced ovarian cancer

Thomas Högberg

Medical oncology

Research output: Contribution to journal › Debate/Note/Editorial

Abstract

Dose-dense administration of paclitaxel as well as intraperitoneal administration of platinum and paclitaxel as first-line treatments provide similar advantages compared with standard treatment in advanced ovarian cancer. Both approaches, however, need to be confirmed by additional studies. a low dose of pegylated liposomal doxorubicin combined with carboplatin is superior to standard paclitaxel and carboplatin in relapsed platinum-sensitive ovarian cancer.

Original language	English
Pages (from-to)	191-193
Journal	Nature Reviews Clinical Oncology
Volume	7
Issue number	4
DOIs	https://doi.org/10.1038/nrclinonc.2010.37
Publication status	Published - 2010

Subject classification (UKÄ)

Cancer and Oncology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1038/nrclinonc.2010.37

http://www.ncbi.nlm.nih.gov/pubmed/20354543?dopt=Abstract

Cite this

@article{796086d91ee84c5c9fcc2df37c248905,

title = "CHEMOTHERAPY Current drugs still have potential in advanced ovarian cancer",

abstract = "Dose-dense administration of paclitaxel as well as intraperitoneal administration of platinum and paclitaxel as first-line treatments provide similar advantages compared with standard treatment in advanced ovarian cancer. Both approaches, however, need to be confirmed by additional studies. a low dose of pegylated liposomal doxorubicin combined with carboplatin is superior to standard paclitaxel and carboplatin in relapsed platinum-sensitive ovarian cancer.",

author = "Thomas H{\"o}gberg",

year = "2010",

doi = "10.1038/nrclinonc.2010.37",

language = "English",

volume = "7",

pages = "191--193",

journal = "Nature Reviews Clinical Oncology",

issn = "1759-4782",

publisher = "Nature Publishing Group",

number = "4",

}

TY - JOUR

T1 - CHEMOTHERAPY Current drugs still have potential in advanced ovarian cancer

AU - Högberg, Thomas

PY - 2010

Y1 - 2010

N2 - Dose-dense administration of paclitaxel as well as intraperitoneal administration of platinum and paclitaxel as first-line treatments provide similar advantages compared with standard treatment in advanced ovarian cancer. Both approaches, however, need to be confirmed by additional studies. a low dose of pegylated liposomal doxorubicin combined with carboplatin is superior to standard paclitaxel and carboplatin in relapsed platinum-sensitive ovarian cancer.

AB - Dose-dense administration of paclitaxel as well as intraperitoneal administration of platinum and paclitaxel as first-line treatments provide similar advantages compared with standard treatment in advanced ovarian cancer. Both approaches, however, need to be confirmed by additional studies. a low dose of pegylated liposomal doxorubicin combined with carboplatin is superior to standard paclitaxel and carboplatin in relapsed platinum-sensitive ovarian cancer.

U2 - 10.1038/nrclinonc.2010.37

DO - 10.1038/nrclinonc.2010.37

M3 - Debate/Note/Editorial

C2 - 20354543

SN - 1759-4782

VL - 7

SP - 191

EP - 193

JO - Nature Reviews Clinical Oncology

JF - Nature Reviews Clinical Oncology

IS - 4

ER -

CHEMOTHERAPY Current drugs still have potential in advanced ovarian cancer

Abstract

Subject classification (UKÄ)

UN SDGs

Access to Document

Fingerprint

Cite this